Skip to main content
Figure 1 | Journal of Neuroinflammation

Figure 1

From: The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

Figure 1

Clinical Rating Score and Fine Motor Skills task. (A) Clinical rating showed a progressive improvement of the hemiparkinsonian features, which reached statistical significance at 9 and 11 weeks (Kruskal-Wallis test; *P = 0.014, **P = 0.02, respectively). (B) During the fine motor skills task, the placebo-treated monkeys failed to complete the test with the left hand (hand contralateral to intracarotid MPTP administration) while some pioglitazone- treated monkeys improved their performance. Due to individual variability, a statistical significant difference was found only in the third week post-treatment in the 5.0 mg/kg treatment group compared to placebo (*Repeated measures ANOVA; P = 0.023).

Back to article page